INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	899-73077-04
Application Number	10/564,369
Filing Date	August 23, 2006
First Named Inventor	Nelson
Art Unit	1635
Examiner Name	Not yet assigned

		Examiner Name 110t yet assigned			
Examiner's Initials*	Cite No. (optional)	other documents			
SV		Branch A., "A good antisense molecule is hard to find," TIBS 23:45-20, February 1998			
5~		Fleming, et al., "Regulation of vascular endothelial growth factor expression in human colon carcinoma cells by activity of src kinase," Surgery 122:50-507, 1997			
5~		Jen and Gewirtz, "Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies," Stem Cells 18:307-319, 2000			
	!				
	~~				

EXAMINER SIGNATURE: DATE CONSIDERED: 10/19/07	7
---	---

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

SAS:dsh	705/12/06	899-73077-04	474091	737

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	899-73077-04	
Application Number	10/564,369	
Filing Date	January 11, 2006	
First Named Inventor	Nelson	
Art Unit		
Examiner Name		

MAY 1 5 7006

U.S. PATENT DOCUMENTS

opies of U.S. atent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent medical time issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
Examiner's Initials*	Cite No.		ro	HER DOCUMENTS	

Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS
SV	,	Guan et al., "Design and synthesis of aminopropyl tetrahydoindole-based indolin-2-ones as selective and potent inhibitors of Src and Yes tyrosine kinase," <i>Bioorganic & Medicinal Chemistry Letters</i> 14:187-190 (2004)
50		Macdonald et al., "The hepatitis C virus NS5A protein binds to members of the Src family of tyrosine kinases and regulates kinase activity," J. General Virology 85:721-729 (2004)
52		Missbach et al., "A Novel Inhibitor of the Tyrosine Kinase Src Suppresses Phosphorylation of Its Major Cellular Substrates and Reduces Bone Resorption In Vitro and in Rodent Models In Vivo," Bone 24(5):437-449 (1999)
5~		Moasser et al., "Inhibition of Src Kinases by a Selective Tyrosine Kinase Inhibitor Causes Mitotic Arrest," Cancer Research 59:6145-6152 (1999)
5~		Schang, "Effects of pharmacological cyclin-dependent kinase inhibitors on viral transcription and replication," <i>Biochimica et Biophysica Acta</i> 1697:197-209 (2004)

EXAMINER SIGNATURE:	S. Wang	DATE CONSIDERED:	10/19/07

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.